185
Participants
Start Date
October 31, 2024
Primary Completion Date
December 31, 2028
Study Completion Date
February 28, 2029
Standard chemotherapy
Each patient will receive the standard first-line chemotherapy (chosen among Gemcitabine-Abraxane, or Abraxane-Gemcitabine-FOLFOX or FOLFIRINOX, based on the clinical judgement of the treating oncologist) until disease progression.
Organoid-guided treatment
Upon disease progression confirmed radiologically, the patients will receive second-line chemotherapy. Second-line chemotherapy will be selected among the most promising effective drug (or drug regimens) as predicted in vitro by their benchmarking on patient-derived organoids.
Klinik Hirslanden, Zurich
OTHER
Prof. Dr. med. Dres. h.c. Jan Schmidt, MME
OTHER